欧州のCAR-T細胞療法治療市場 – 業界動向と2028年までの予測

Customize Your Report レポートをカスタマイズする Buy Now 今すぐ購入 Free Sample Report 無料サンプルレポート
Home Pharmaceutical 欧州のCAR
Request for TOC TOC のリクエスト Speak to Analyst アナリストに相談する Buy Now今すぐ購入 Inquire Before Buying 事前に問い合わせる Free Sample Report 無料サンプルレポート

欧州のCAR-T細胞療法治療市場 – 業界動向と2028年までの予測

  • Pharmaceutical
  • Published Report
  • May 2021
  • Europe
  • 350 ページ
  • テーブル数: 215
  • 図の数: 51
Buy Now 今すぐ購入

>ヨーロッパのCAR-T細胞療法治療市場、製品別（自己CAR-T細胞、同種CAR-T細胞）、構造別（第1世代CAR-T細胞、第2世代CAR-T細胞、第3世代CAR-T細胞、第4世代CAR-T細胞）、標的抗原（固形腫瘍抗原、血液悪性腫瘍抗原、その他）、ブランド別（Yescarta、Kymriah、Tecartus、その他）、治療用途別（血液悪性腫瘍、膵臓がん、乳がん、肺がん、胃がん、多発性骨髄腫、慢性リンパ性白血病、マントル細胞リンパ腫、濾胞性リンパ腫、びまん性大細胞型B細胞リンパ腫、急性リンパ芽球性白血病、その他）、エンドユーザー別（病院、専門クリニック、その他）、流通チャネル別（病院薬局、その他）、国別(ドイツ、イギリス、フランス、イタリア、スペイン、オランダ、ロシア、スイス、トルコ、オーストリア、ノルウェー、ハンガリー、リトアニア、アイルランド、ポーランド、その他のヨーロッパ諸国) 2028 年までの業界動向と予測

欧州CAR-T細胞療法治療市場

市場分析と洞察：欧州CAR-T細胞療法治療市場

CAR-T細胞療法治療市場は、2021年から2028年の予測期間に市場成長を遂げると予想されています。データブリッジマーケットリサーチは、市場は2021年から2028年の予測期間に29.4%のCAGRで成長し、2028年までに105億9,465万米ドルに達すると分析しています。がんや感染症の治療におけるCAR-T細胞療法の使用の増加が、CAR-T細胞療法治療市場の成長の原動力となっています。

CAR-T 細胞療法またはキメラ抗原受容体 T 細胞は、さまざまな癌の治療のための免疫療法として使用できる人工 T 細胞受容体を生成するために遺伝子操作されたT 細胞です。キメラ抗原受容体は、特定のタンパク質を標的とする新しい能力を T 細胞に提供するために研究室で操作された受容体タンパク質です。

免疫療法に関する認識の高まりにより、人々はさまざまな種類のCAR-T療法とその有効性を知るようになり、CAR-T細胞療法治療市場の推進力となっています。治療の副作用により、一部の人々はそのような治療を選択することが制限され、それが製品価値に影響を与え、CAR-T細胞療法治療市場の成長の抑制要因となっています。パイプライン製品の存在は、市場プレーヤーが革新的な医薬品の製造に常に取り組んでいることを示唆しており、CAR-T細胞療法治療市場にとっての機会となっています。免疫療法の承認に時間がかかると、製品メーカーが市場で潜在的な利益を得ることが制限され、市場規模全体に影響を及ぼし、CAR-T細胞療法治療市場の成長にとって課題となっています。

CAR-T 細胞療法治療市場レポートでは、市場シェア、新開発、製品パイプライン分析、国内および現地の市場プレーヤーの影響の詳細、新たな収益源、市場規制の変更、製品承認、戦略的決定、製品発売、地理的拡大、市場における技術革新の観点から見た機会の分析が提供されます。分析と市場シナリオを理解するには、アナリスト概要についてお問い合わせください。当社のチームが、希望する目標を達成するための収益影響ソリューションの作成をお手伝いします。

欧州CAR-T細胞療法治療市場

欧州CAR-T細胞療法治療市場の範囲と市場規模

CAR-T 細胞療法治療市場は、製品、構造、標的抗原、ブランド、治療用途、エンドユーザー、流通チャネルに基づいてセグメント化されています。セグメント間の成長は、ニッチな成長分野と市場へのアプローチ戦略を分析し、コアアプリケーション領域とターゲット市場の違いを決定するのに役立ちます。

  • 製品に基づいて、CAR-T細胞療法治療市場は、自己CAR-T細胞と同種CAR-T細胞に分類されます。2021年には、CAR-T細胞療法に承認された薬剤が本質的に自己由来であるため、自己CAR-T細胞セグメントがCAR-T細胞療法治療市場を支配すると予想されます。
  • 構造に基づいて、CAR-T細胞療法治療市場は、第1世代CAR-T細胞、第2世代CAR-T細胞、第3世代CAR-T細胞、第4世代CAR-T細胞に分類されます。2021年には、承認された治療法が第2世代ベースの構造であるため、第2世代CAR-T細胞セグメントがCAR-T細胞療法治療市場を支配すると予想されます。
  • 標的抗原に基づいて、CAR-T細胞療法治療市場は、固形腫瘍抗原、血液悪性腫瘍抗原、その他に分類されます。2021年には、CAR-T細胞療法用に承認された薬剤が主に血液悪性腫瘍に使用され、大規模な研究開発が進行中であるため、血液悪性腫瘍抗原セグメントがCAR-T細胞療法治療市場を支配すると予想されます。 
  • ブランドに基づいて、CAR-T細胞療法治療市場は、イエスカルタ、キムリア、テカルタスなどに分類されます。イエスカルタは腫瘍治療クラスで最初に承認されたCAR-T細胞療法であるため、2021年にはイエスカルタセグメントがCAR-T細胞療法治療市場を支配すると予想されます。 
  • 治療用途に基づいて、CAR-T細胞療法治療市場は、血液悪性腫瘍、膵臓がん、乳がん、肺がん、胃がん、多発性骨髄腫、慢性リンパ性白血病、マントル細胞リンパ腫、濾胞性リンパ腫、びまん性大細胞型B細胞リンパ腫、急性リンパ芽球性白血病などに分類されます。2021年には、Yescartaが市場の主要な収益を占め、濾胞性リンパ腫がYescartaの主な適応症であるため、血液悪性腫瘍セグメントがCAR-T細胞療法治療市場を支配すると予想されます。
  • エンドユーザーに基づいて、CAR-T細胞療法治療市場は、病院、専門クリニック、その他に分類されます。2021年には、CAR-T細胞療法には高度な技術研究所を備えた高度な訓練を受けた専門家が必要であるため、病院セグメントがCAR-T細胞療法治療市場を支配しています。 
  • 流通チャネルに基づいて、CAR-T細胞療法治療市場は、病院薬局とその他に分類されます。病院薬局は病院の中心部であり、すべての点滴関連および投薬関連の配送は薬局部門によって販売されるため、2021年には病院薬局セグメントがCAR-T細胞療法治療流通チャネルを支配すると予想されます。

CAR-T細胞療法治療市場の国別分析

CAR-T 細胞療法治療市場は分析され、上記の国、製品、構造、標的抗原、ブランド、治療用途、エンドユーザー、流通チャネルに基づいて市場規模の情報が提供されます。

ヨーロッパの CAR-T 細胞療法治療市場レポートで取り上げられている国は、ドイツ、イギリス、フランス、イタリア、スペイン、オランダ、ロシア、スイス、トルコ、オーストリア、ノルウェー、ハンガリー、リトアニア、アイルランド、ポーランド、その他のヨーロッパ諸国です。

ドイツでは、がんの蔓延により、自己 CAR-T 細胞セグメントがヨーロッパの CAR-T 細胞療法治療市場を支配しています。

レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、各国の市場シナリオを予測するために使用される主要な指標の一部です。また、国別データの予測分析を提供する際には、ヨーロッパ ブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、販売チャネルの影響も考慮されます。

免疫療法に関する認知度の高まりがCAR-T細胞療法治療市場の成長を後押し 

CAR-T 細胞療法治療市場では、CAR-T 細胞療法治療の売上、CAR-T 細胞療法治療技術の進歩の影響、CAR-T 細胞療法治療市場へのサポートに関する規制シナリオの変化など、CAR-T 細胞療法治療産業の各国での成長に関する詳細な市場分析も提供しています。データは 2011 年から 2019 年までの履歴期間について入手できます。

競争環境とCAR-T細胞療法治療市場シェア分析

CAR-T 細胞療法治療市場の競争状況は、競合他社ごとに詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品試験パイプライン、製品の承認、特許、製品の幅と幅、アプリケーションの優位性、技術ライフライン曲線などがあります。提供されている上記のデータ ポイントは、CAR-T 細胞療法治療市場に関連する会社の焦点にのみ関連しています。

CAR-T細胞療法治療市場レポートを扱っている主要企業には、Autolus、Amgen Inc.、bluebird bio, Inc.、Adaptimmune Therapeutics plc.、Bristol-Myers Squibb Company、Johnson & Johnson Services, Inc.、AbbVie Inc.、Novartis AG、Kite Pharma (Gilead Sciences, Inc. の子会社)、Cellectis、TC BIOPHARM、Celyad Oncologyなど、国内外の企業があります。DBMRアナリストは、競争上の強みを理解し、各競合他社の競合分析を個別に提供します。  

 世界中の企業によって多くの製品の発売や契約も開始されており、CAR-T細胞療法治療市場の成長を加速させています。

例えば、

  • 2020年12月、Atara Biotherapeutics, Inc.は、固形腫瘍に対するメソテリン標的CAR-T細胞療法の開発でBayer AGと提携しました。契約に基づき、同社は悪性胸膜中皮腫と非小細胞肺がんの治療薬としてATA2271の開発に注力しています。この提携により、同社のATA2271の研究開発が加速し、同種CAR-T細胞療法の大手メーカーになることができました。

市場プレーヤーによるコラボレーション、製品の発売、事業拡大、賞や表彰、合弁事業、その他の戦略により、CAR-T細胞療法治療市場における企業市場が強化され、組織がCAR-T細胞療法治療の提供を改善するメリットももたらされます。 

SKU-

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

Sample Image 画像をクリックすると拡大します
  • インタラクティブなデータ分析ダッシュボード
  • 成長の可能性が高い機会のための企業分析ダッシュボード
  • カスタマイズとクエリのためのリサーチアナリストアクセス
  • インタラクティブなダッシュボードによる競合分析
  • 最新ニュース、更新情報、トレンド分析
  • 包括的な競合追跡のためのベンチマーク分析のパワーを活用
デモのリクエスト

目次

  1. introduction
    1. OBJECTIVES OF THE STUDY
    2. MARKET DEFINITION
    3. OVERVIEW of EUROPE CAR-T cell therapy treatment MARKET
    4. LIMITATIONs
    5. MARKETS COVERED
  2. MARKET SEGMENTATION
    1. MARKETS COVERED
    2. geographical scope
    3. years considered for the study
    4. currency and pricing
    5. DBMR TRIPOD DATA VALIDATION MODEL
    6. MULTIVARIATE MODELLING
    7. PRODUCT LIFELINE CURVE
    8. primary interviews with key opinion leaders
    9. DBMR MARKET POSITION GRID
    10. vendor share analysis
    11. MARKET product COVERAGE GRID
    12. secondary sourcEs
    13. assumptions
  3. EXECUTIVE SUMMARY
  4. premium insight
  5. Epidemiology
  6. Pipeline analysis
  7. Market Overview
    1. Drivers
      1. increase in usage of CAR-T CELL THERAPY for the treatment of cancer and infectious diseases
      2. increasing prevalEnce of cancer
      3. rise in awareness about immunotherapies
      4. increasing investment in research and development
      5. adoption of CAR-T cell therapy treatment in Emerging markets
    2. restraints
      1. adverse side effects of therapies
      2. high cost associated with therapies
      3. logistic challenge associated with CAR-T therapies
      4. availability of alternatives for tumor treatment
    3. opportunities
      1. presence of pipeline producTs
      2. strategiC initiatives by market players
      3. Rise in expenditure in healthcare sector
    4. challenges
      1. long approval time for immunotherapies
      2. lack of skilled professionals
  8. IMPACT OF COVID-19 ON EUROPE CAR-T CELL THERAPY TREATMENT MARKET
    1. IMPACT ON PRICE
    2. IMPACT ON DEMAND
    3. IMPACT ON SUPPLY CHAIN
    4. STRATEGIC DECISION FOR MANUFACTURERS
    5. CONCLUSION
  9. Europe CAR-T Cell Therapy Treatment MARKET, BY PRODUCT
    1. overview
    2. Autologous CAR-T Cells
    3. Allogeneic CAR-T Cells
  10. Europe CAR-T CELL THERAPY TREATMENT MARKET, BY Structure
    1. overview
    2. First Generation CAR-T Cells
    3. Second Generation CAR-T Cells
    4. Third Generation CAR-T Cells
    5. Fourth Generation CAR-T Cells
  11. Europe CAR-T CELL THERAPY TREATMENTMARKET, BY Targeted Antigens
    1. overview
    2. Antigens on Hematologic Malignancies
      1. Cluster of Differentiation-19 (CD-19)
      2. Cluster of Differentiation-30 (CD-30)
      3. Cluster of Differentiation-22 (CD-22)
      4. Cluster of Differentiation-20 (CD-20)
      5. Cluster of Differentiation-33 (CD-33)
    3. Antigens on Solid Tumors
      1. Human Epidermal Growth Factor Receptor-2 (HER-2)
      2. Epidermal Growth Factor Receptors Variant III (EGFRV-III)
      3. Mesothelin (MSLN)
      4. Prostate-Specific Membrane Antigen (PSMA)
      5. Interleukin-13RA2 (IL13RA2)
      6. Disialoganglioside 2 (GD2)
      7. Glypican-3 (GPC3)
      8. Others
    4. OTHERS
  12. Europe CAR-T cell therapy treatment MARKET, BY brand
    1. overview
    2. yescarta
    3. KYMRIAH
    4. TECARTUS
    5. others
  13. Europe CAR-T cell therapy treatment MARKET, BY therapeutic application
    1. overview
    2. Follicular Lymphoma
    3. Diffuse Large B-Cell Lymphoma
    4. Acute Lymphoblastic Leukaemia (ALL)
    5. Mantle Cell Lymphoma
    6. Multiple Myeloma
    7. Hematologic Malignancies
      1. Leukemia
      2. Lymphoma
      3. Myeloma
      4. Others
    8. Lung Cancer
    9. Chronic Lymphocytic Leukemia
    10. Gastric Cancer
    11. Pancreatic Cancer
    12. Breast Cancer
    13. others
  14. Europe CAR-T cell therapy treatment MARKET, BY end user
    1. overview
    2. hospitals
    3. Specialty Clinics
    4. others
  15. Europe CAR-T cell therapy treatment MARKET, BY distribution channel
    1. overview
    2. hospital Pharmacy
    3. others
  16. Europe CAR-T cell therapy treatment market by geography
    1. EUROPE
      1. germany
      2. u.k
      3. France
      4. Italy
      5. Spain
      6. NETHERLANDS
      7. Russia
      8. Switzerland
      9. Belgium
      10. Turkey
      11. Austria
      12. Norway
      13. Hungary
      14. Lithuania
      15. Ireland
      16. Poland
      17. Rest of Europe
  17. Europe CAR-T Cell Therapy Treatment Market: COMPANY landscape
    1. company share analysis: europe
  18. swot analysis
  19. company profile
    1. kite pharma (A subsidiary of GILEAD SCIENCES, INC.)
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. company share analysis
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENTS
    2. Novartis AG
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. company share analysis
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENTS
    3. Abbvie inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    4. Adaptimmune Therapeutics plc
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    5. Amgen Inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PIPELINE PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    6. Atara Biotherapeutics, Inc.
      1. COMPANY SNAPSHOT
      2. PIPELINE PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    7. aurora biopharmA
      1. COMPANY SNAPSHOT
      2. PIPELINE PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    8. Autolus
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    9. Bellicum Phamaceuticals, Inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    10. BioAtla Inc.
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    11. bluebird bio, inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    12. Bristol-Myers Squibb Company
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    13. carina biotech
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    14. cartherics pty ltd
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    15. cartesian therapeutics, inc.
      1. COMPANY SNAPSHOT
      2. PIPELINE PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    16. cellectis SA
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    17. celyad oncology SA
      1. COMPANY SNAPSHOT
      2. PIPELINE PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    18. Johnson & Johnson Services, Inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    19. sorrento therapeutics, INC.
      1. COMPANY SNAPSHOT
      2. PIPELINE PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    20. tc biopharm Limited
      1. COMPANY SNAPSHOT
      2. PIPELINE PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    21. tessa therapeutics ltd.
      1. COMPANY SNAPSHOT
      2. PIPELINE PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    22. tmunity therapeutics
      1. COMPANY SNAPSHOT
      2. PIPELINE PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    23. mustang bio
      1. COMPANY SNAPSHOT
      2. PIPELINE PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    24. Xyphos (A Subsidiary of Astellas Pharma Inc.)
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PIPELINE PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    25. ziopharm oncology, inc.
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
  20. questionnaire
  21. related reports

表のリスト

TABLE 1 Europe CAR-T cell therapy treatment Market, pipeline analysis

TABLE 2 Below provided are the alternative chemotherapies of CAR-T cell therapy:

TABLE 3 TOTAL HEALTH SPENDING BY THE U.S. (2015-2016)

TABLE 4 Europe CAR-T CELL THERAPY TREATMENTMarket, By MOLECULE, 2019-2028 (USD Million)

TABLE 5 Europe Autologous CAR-T Cells in CAR-T CELL THERAPY TREATMENTMarket, By Region, 2017-2028 (USD Million)

TABLE 6 Europe Allogeneic CAR-T Cells in CAR-T CELL THERAPY TREATMENTMARKET, By Region, 2019-2028 (USD Million)

TABLE 7 Europe CAR-T CELL THERAPY TREATMENTMarket, By Structure, 2019-2028 (USD Million)

Celyad is engaged in the manufacturing of CYAD-211, a first generation CAR-T cell therapy expressing BCMA targeting chimeric antigen receptor which interferes with the expression of the CD3ζ of T cell receptor complex.

TABLE 8 Europe First Generation CAR-T Cells in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)

TABLE 9 Europe Second Generation CAR-T Cells in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)

TABLE 10 Europe Third Generation CAR-T Cells in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)

TABLE 11 Europe Third Generation CAR-T Cells in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)

TABLE 12 Europe CAR-T CELL THERAPY TREATMENTMarket, By targeted antigens, 2019-2028 (USD Million)

TABLE 13 Europe Antigens on Hematologic Malignancies in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)

TABLE 14 Europe Antigens on Hematologic Malignancies in CAR-T CELL THERAPY TREATMENT Market, By Antigens on Hematologic Malignancies, 2019-2028 (USD Million)

TABLE 15 Europe Antigens on Solid Tumors in CAR-T CELL THERAPY TREATMENTMarket , By Region, 2017-2028 (USD Million)

TABLE 16 Europe Antigens on Solid Tumors in CAR-T CELL THERAPY TREATMENT Market, By Antigens on Solid Tumors, 2019-2028 (USD Million)

TABLE 17 Europe others in CAR-T CELL THERAPY TREATMENTMarket , By Region, 2017-2028 (USD Million)

TABLE 18 Europe YESCARTA in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 19 Europe YESCARTA in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 20 Europe KYMRIAH in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 21 Europe TECARTUS in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 22 Europe others in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 23 Europe CAR-T cell therapy treatment Market, By therapeutic type, 2019-2028 (USD Million)

TABLE 24 Europe Follicular Lymphoma in CAR-T cell therapy treatment Market, By therapeutic type, 2017-2028 (USD Million)

TABLE 25 Europe Diffuse Large B-Cell Lymphoma in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 26 Europe ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 27 Europe Mantle Cell Lymphoma in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 28 Europe Multiple Myeloma in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 29 Europe hematologic malignancies in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 30 Europe hematologic malignancies on Solid Tumors in CAR-T CELL THERAPY TREATMENT Market, By therapeutic application, 2019-2028 (USD Million)

TABLE 31 Europe Lung Cancer in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 32 Europe chronic lymphocytic leukemia in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 33 Europe gastric cancer in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 34 Europe pancreatic cancer in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 35 Europe breast cancer in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 36 Europe others in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 37 Europe CAR-T cell therapy treatment Market, By END USER, 2019-2028 (USD Million)

TABLE 38 Europe hospitals in CAR-T cell therapy treatment Market, By therapeutic type, 2017-2028 (USD Million)

TABLE 39 Europe specialty clinics in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 40 Europe others in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 41 Europe CAR-T cell therapy treatment Market, By distribution channel, 2019-2028 (USD Million)

TABLE 42 Europe hospital pharmacy in CAR-T cell therapy treatment Market, By distribution channel, 2017-2028 (USD Million)

TABLE 43 Europe others in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 44 Europe CAR-T Cell Therapy Treatment Market, By Region, 2019-2028 (USD Million)

TABLE 45 Europe CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 46 Europe CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 47 Europe CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 48 europe Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 49 Europe Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 50 Europe CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 51 Europe CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 52 Europe Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 53 Europe CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 54 Europe CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 55 Germany CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 56 Germany CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 57 Germany CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 58 Germany Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 59 Germany Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 60 Germany CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 61 Germany CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 62 Germany Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 63 Germany CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 64 Germany CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 65 U.K CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 66 U.K CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 67 U.K CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 68 U.K Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 69 U.K Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 70 U.K CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 71 U.K CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 72 U.K Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 73 U.K CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 74 U.K CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 75 FRANCE CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 76 FRANCE CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 77 FRANCE CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 78 FRANCE Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 79 FRANCE Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 80 FRANCE CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 81 FRANCE CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 82 FRANCE Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 83 FRANCE CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 84 FRANCE CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 85 ITALY CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 86 ITALY CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 87 ITALY CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 88 ITALY Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 89 ITALY Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 90 ITALY CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 91 ITALY CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 92 ITALY Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 93 ITALY CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 94 ITALY CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 95 Spain CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 96 SPAIN CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 97 SPAIN CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 98 SPAIN Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 99 SPAIN Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 100 SPAIN CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 101 SPAIN CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 102 SPAIN Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 103 SPAIN CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 104 SPAIN CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 105 netherlands CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 106 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 107 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 108 NETHERLANDS Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 109 NETHERLANDS Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 110 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 111 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 112 NETHERLANDS Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 113 NETHERLANDS CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 114 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 115 Russia CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 116 RUSSIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 117 RUSSIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 118 RUSSIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 119 RUSSIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 120 RUSSIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 121 RUSSIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 122 RUSSIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 123 RUSSIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 124 RUSSIA CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 125 Switzerland CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 126 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 127 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 128 SWITZERLAND Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 129 SWITZERLAND Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 130 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 131 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 132 SWITZERLAND Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 133 SWITZERLAND CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 134 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 135 belgium CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 136 BELGIUM CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 137 BELGIUM CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 138 BELGIUM Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 139 BELGIUM Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 140 BELGIUM CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 141 BELGIUM CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 142 BELGIUM Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 143 BELGIUM CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 144 BELGIUM CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 145 turkey CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 146 TURKEY CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 147 TURKEY CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 148 TURKEY Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 149 TURKEY Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 150 TURKEY CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 151 TURKEY CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 152 TURKEY Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 153 TURKEY CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 154 turkey CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 155 Austria CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 156 AUSTRIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 157 AUSTRIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 158 AUSTRIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 159 AUSTRIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 160 AUSTRIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 161 AUSTRIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 162 AUSTRIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 163 AUSTRIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 164 Austria CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 165 norway CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 166 NORWAY CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 167 NORWAY CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 168 NORWAY Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 169 NORWAY Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 170 NORWAY CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 171 NORWAY CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 172 NORWAY Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 173 NORWAY CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 174 Norway CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 175 Hungary CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 176 HUNGARY CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 177 HUNGARY CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 178 HUNGARY Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 179 HUNGARY Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 180 HUNGARY CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 181 HUNGARY CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 182 HUNGARY Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 183 HUNGARY CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 184 Hungary CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 185 Lithuania CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 186 LITHUANIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 187 LITHUANIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 188 LITHUANIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 189 LITHUANIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 190 LITHUANIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 191 LITHUANIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 192 LITHUANIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 193 LITHUANIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 194 Lithuania CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 195 Ireland CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 196 IRELAND CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 197 IRELAND CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 198 IRELAND Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 199 IRELAND Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 200 IRELAND CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 201 IRELAND CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 202 IRELAND Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 203 IRELAND CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 204 ireland CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 205 Poland CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 206 POLAND CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 207 POLAND CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 208 POLAND Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 209 POLAND Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 210 POLAND CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 211 POLAND CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 212 POLAND Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 213 POLAND CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 214 Poland CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 215 Rest of Europe CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

図表一覧

FIGURE 1 Europe CAR-T cell therapy treatment MARKET: SEGMENTATION

FIGURE 2 EUROPE CAR-T cell therapy treatment MARKET: DATA TRIANGULATION

FIGURE 3 Europe CAR-T cell therapy treatment Market: DROC ANALYSIS

FIGURE 4 Europe CAR-T cell therapy treatment market: Europe VS REGIONAL MARKET ANALYSIS

FIGURE 5 Europe CAR-T cell therapy treatment Market: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE CAR-T cell therapy treatment MARKET: MULTIVARIATE MODELLING

FIGURE 7 EUROPE CAR-T cell therapy treatment MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 EUROPE CAR-T cell therapy treatment MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE CAR-T cell therapy treatment MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE car-t cell therapy treatment MARKET: MARKET product COVERAGE GRID

FIGURE 11 Europe car-t cell therapy treatment market: SEGMENTATION

FIGURE 12 increasing investment in research and development is expected to drive THE Europe CAR-T cell therapy treatment market IN THE FORECAST PERIOD OF 2021 to 2028

FIGURE 13 Autologus car-t cells SEGMENT is expected to account for the largest share of the Europe CAR-T CELL THERAPY TREATMENT market in 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGEs OF Europe CAR-T cell therapy treatment Market

FIGURE 15 New Cancer Cases Worldwide, (2018)

FIGURE 16 Europe Cancer Incidence (2018)

FIGURE 17 Cancer Death By Type (in million), world, 2017

FIGURE 18 Europe CAR-T CELL THERAPY TREATMENTmarket: BY Product, 2021

FIGURE 19 Europe CAR-T CELL THERAPY TREATMENTmarket: BY Product, 2019-2028 (USD Million)

FIGURE 20 Europe CAR-T CELL THERAPY TREATMENTmarket: BY Product, CAGR (2021-2028)

FIGURE 21 Europe CAR-T CELL THERAPY TREATMENTmarket: BY Product, LIFELINE CURVE

FIGURE 22 Europe CAR-T CELL THERAPY TREATMENTmarket: BY structure, 2021

FIGURE 23 Europe CAR-T CELL THERAPY TREATMENTmarket: BY structure, 2019-2028 (USD Million)

FIGURE 24 Europe CAR-T CELL THERAPY TREATMENTmarket: BY structure, CAGR (2021-2028)

FIGURE 25 Europe CAR-T CELL THERAPY TREATMENTmarket: BY structure, LIFELINE CURVE

FIGURE 26 Europe CAR-T CELL THERAPY TREATMENTmarket: BY targeted antigens, 2021

FIGURE 27 Europe CAR-T CELL THERAPY TREATMENTmarket: BY targeted antigens, 2019-2028 (USD Million)

FIGURE 28 Europe CAR-T CELL THERAPY TREATMENTmarket: BY targeted antigens, CAGR (2021-2028)

FIGURE 29 Europe CAR-T CELL THERAPY TREATMENTmarket: BY targeted antigens, LIFELINE CURVE

FIGURE 30 Europe CAR-T cell therapy treatment market: BY brand, 2020

FIGURE 31 Europe CAR-T cell therapy treatment market: BY brand, 2020-2028 (USD Million)

FIGURE 32 Europe CAR-T cell therapy treatment market: BY brand, CAGR (2020-2028)

FIGURE 33 Europe CAR-T cell therapy treatment market: BY brand, LIFELINE CURVE

FIGURE 34 Europe CAR-T cell therapy treatment market: BY therapeutic application, 2020

FIGURE 35 Europe CAR-T cell therapy treatment market: BY therapeutic application, 2020-2028 (USD Million)

FIGURE 36 Europe CAR-T cell therapy treatment market: BY therapeutic application, CAGR (2020-2028)

FIGURE 37 Europe CAR-T cell therapy treatment market: BY therapeutic application, LIFELINE CURVE

FIGURE 38 Europe CAR-T cell therapy treatment market: BY END USER, 2020

FIGURE 39 Europe CAR-T cell therapy treatment market: BY END USER, 2020-2028 (USD Million)

FIGURE 40 Europe CAR-T cell therapy treatment market: BY END USER, CAGR (2020-2028)

FIGURE 41 Europe CAR-T cell therapy treatment market: BY END USER, LIFELINE CURVE

FIGURE 42 Europe CAR-T cell therapy treatment market: BY distribution channel, 2020

FIGURE 43 Europe CAR-T cell therapy treatment market: BY distribution channel, 2020-2028 (USD Million)

FIGURE 44 Europe CAR-T cell therapy treatment market: BY distribution channel, CAGR (2020-2028)

FIGURE 45 Europe CAR-T cell therapy treatment market: BY distribution channel, LIFELINE CURVE

FIGURE 46 Europe CAR-T CELL THERAPY TREATMENT market: SNAPSHOT (2020)

FIGURE 47 Europe CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020)

FIGURE 48 Europe CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2021 & 2028)

FIGURE 49 Europe CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020 & 2028)

FIGURE 50 Europe CAR-T CELL THERAPY TREATMENT market: BY product (2021-2028)

FIGURE 51 EUROPE CAR-T Cell Therapy Treatment Market: company share 2020 (%)

詳細情報を見る Right Arrow

調査方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。

関連ページを閲覧する

Banner